Background. Tobramycin Inhalation Solution (TIS) for chronic suppressive therapy or eradication of Pseudomonas aeruginosais standard for patients with cystic fibrosis. Increasingly, TIS is used off-label to treat other infectious complications of the respiratory tract. Children in pediatric long term care facilities ( pLTCFs) have complex comorbid conditions often including respiratory disorders, e.g., bronchopulmonary dysplasia and chronic lung disease. We sought to describe the use of TIS in pLTCFs.
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Methods. From October 2013 to March 2014 we reviewed the medical records of all children residing at 3 pLTCFs in the New York metropolitan area to determine if they had received TIS and if so, the indication for treatment. Statistical analyses were completed with Student's t-test or Pearson's chi-square.
Results. During the study period, 8% of residents (25/314) were treated with TIS (10, 8, and 7 were at Site 1, 2, and 3, respectively). The most common indication was tracheitis (n = 10, 40%) followed by "secretion management" (n = 5, 20%). Other indications included atelectasis (n = 2), prophylaxis (n = 2), reactive airway disease (n = 1), and tracheal colonization (n = 1). No indication was documented for 4 (16%) residents. Most residents (n = 15) were on TIS courses of monthly on-off cycles and 10 received 1 course (range: 4-21 days). Bacterial cultures of the respiratory tract were obtained for 5 (20%) of 25 residents on TIS and were positive for Serratia marcescens (n = 2), P. aeruginosa (n = 2), and both S. marescens and P. aeruginosa(n = 1). Susceptibility testing was available for 4 isolates and all were susceptible to tobramycin. Residents who received TIS were older and more likely to have a tracheostomy and a chronic respiratory disorder (Table) . 
